Digitalisation the key to efficient EU pharmaceutical regulation and easing of localised drug shortages
Current EU regulatory systems too overwhelmed by paper, head of European association representing generics, biosimilars and value added medicines industries tells CPHI Worldwide online conference
Digitalisation is needed to update inefficient and paper-based European pharmaceutical regulatory systems as well as help ease localised medicines shortages in European Union member states, according to Adrian van den Hoven, Director General, Medicines for Europe in a keynote address at the CPHI Worldwide online conference Monday.
“The European regulatory system for pharmaceuticals is overwhelmed by too much paper and we could make the system much more efficient for regulators and industry by having digital tools,” he told the CPHI audience. “I suspect there will be a big investment in the digitalisation of the regulatory network in the EU to enable this to go forward.”
He said that despite the single market operating in the EU, different rules, regulations and interpretations around medicines regulation often applied in different Member States.
“Sometimes we have a lot of barriers within the European Union itself. This could be different packaging and leaflet requirements or languages,” he said, “When you have a shortage situation, you want to move excess stock from Country A to Country B in Europe, it’s actually quite difficult to do.”
He said that the EU needs to have much more flexible and efficient rules in order to be able to move medicines very quickly across internal European borders, so I think we’ll move towards a more efficient form of leaflets and packaging, maybe digital forms, to enable this more flexible movement.”
Adrian van den Hoven, Medicines for Europe
Describing three pillars of current European Union pharmaceutical industry focus, he said that largely as a result of COVID-driven stress on pharma supply chains, the European Union is focusing on strategic autonomy, or the ability to self-manufacture certain critical medicines.
He said the second pillar was supply chain resiliency, with a big discussion in Europe ongoing on how to reduce the risk of supply disruptions and shortages.
“The third pillar is European economic recovery – like a lot of regions, the European Union suffered a lot economically and so it’s launched a recovery plan and has in part, targeted the pharma industry,” he added.
He said the EU was investing Eur750 billion to try and push the economy up again: “The interesting thing is that usually these funds target infrastructure or energy but this time they include medicines and active pharmaceutical ingredients (API) production as one of the targets. They want to support investment in the pharmaceutical sector as one of the key objectives of the European recovery.”
“There’s a lot of interest in innovation on the off-patent side in Europe – there’s a very strong interest now in repurposing and reformulation of medicines in European policy,” he said. “This is something that is going to develop over the next year and there are going to be several big projects sponsored by the European Union to encourage this kind of innovation going forward.”
He added that the main challenge to this was the European Union’s current rules on competition which limit how much funding companies can receive “so there has to be a reinterpretation of EU competition law to enable the EU to fund the industry it’s asking to fund.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance